Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. 1992

I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
Oncovirology Laboratory, Centre René Huguenin, St-Cloud, France.

Genetic alterations are believed to be important in the origin and dissemination of breast cancer. Cytogenetic rearrangements on chromosome 7 are common in breast tumours. We used the c-met proto-oncogene probe, which detects sequences on chromosome 7q31, to analyse tumour and blood leucocyte DNA samples from 245 patients with primary breast cancers. The pmetH polymorphic probe detected a high frequency of allele loss (40.5%) among the 121 informative (heterozygous) patients. This genetic alteration was not significantly associated with standard prognostic features including tumour size, histopathological grade, and lymph-node or steroid receptor status. However, patients with loss of heterozygosity on chromosome 7q31 in primary tumour DNA had significantly shorter metastasis-free survival (p = 0.00022) and overall survival (p = 0.0036) after surgery than patients without this alteration. These findings indicate that this region of chromosome 7 might be the site of a breast tumour or metastasis suppressor gene.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D012150 Polymorphism, Restriction Fragment Length Variation occurring within a species in the presence or length of DNA fragment generated by a specific endonuclease at a specific site in the genome. Such variations are generated by mutations that create or abolish recognition sites for these enzymes or change the length of the fragment. RFLP,Restriction Fragment Length Polymorphism,RFLPs,Restriction Fragment Length Polymorphisms
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002872 Chromosome Deletion Actual loss of portion of a chromosome. Monosomy, Partial,Partial Monosomy,Deletion, Chromosome,Deletions, Chromosome,Monosomies, Partial,Partial Monosomies
D002897 Chromosomes, Human, Pair 7 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 7
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
June 1992, Lancet (London, England),
I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
January 1997, Anticancer research,
I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
May 1993, Lancet (London, England),
I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
May 1995, Journal of clinical pathology,
I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
September 1989, Proceedings of the National Academy of Sciences of the United States of America,
I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
August 1995, Genes, chromosomes & cancer,
I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
July 1997, Genes, chromosomes & cancer,
I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
October 2006, Zhonghua wai ke za zhi [Chinese journal of surgery],
I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
August 2002, Archives of oral biology,
I Bièche, and M H Champème, and F Matifas, and K Hacène, and R Callahan, and R Lidereau
October 1996, International journal of oncology,
Copied contents to your clipboard!